Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
An announcement from Lumos Diagnostics Holdings Ltd. ( (AU:LDX) ) is now available.
Lumos Diagnostics has signed a significant six-year exclusive distribution agreement with PHASE Scientific for its FebriDx® product in the U.S. market, valued at up to US$317 million. This agreement marks a pivotal moment for Lumos, as it provides a clear pathway for FebriDx® to enter the U.S. market, pending a CLIA waiver from the FDA. The partnership with PHASE Scientific, known for its rapid diagnostics brand INDICAID®, is expected to enhance the adoption of FebriDx® in urgent care settings, potentially transforming rapid respiratory diagnostics and clinical decision-making.
More about Lumos Diagnostics Holdings Ltd.
Lumos Diagnostics Holdings Ltd. is a leader in rapid, point-of-care diagnostic technologies. The company focuses on developing and commercializing innovative diagnostic solutions that provide quick and accurate results, primarily targeting the healthcare sector.
Average Trading Volume: 1,019,161
Technical Sentiment Signal: Sell
Current Market Cap: A$21.71M
For an in-depth examination of LDX stock, go to TipRanks’ Overview page.